By admin 
When the Department of Defense recently announced that it would implement a mandatory testosterone screening program for all service members aged 30 and older, the decision sent shockwaves through both the military and medical communities. This initiative, championed by Defense Secretary Pete Hegseth, marks an unprecedented shift in how the United States military approaches the biological health and hormonal optimization of its force. While the stated goal is often framed around readiness, lethality, and the long-term wellness of the troops, the move bypasses decades of established medical guidelines and enters a realm of population-level screening that has never been attempted on this scale. As a practicing urologist and health outcomes researcher who has dedicated a career to studying men’s health and the impacts of large-scale screening, I find the prospect of this rollout both fascinating and deeply concerning. The potential for unintended consequences is vast, and if we are to prioritize the actual health of our service members, we must look beyond the surface-level appeal of hormonal optimization.
The scientific foundation of this discussion rests on the hypothalamic-pituitary-gonadal (HPG) axis, a complex feedback loop that regulates the production of testosterone. This system begins in the brain, where the hypothalamus releases gonadotropin-releasing hormone (GnRH), signaling the pituitary gland to produce luteinizing hormone (LH), which in turn stimulates the Leydig cells in the testes to produce testosterone. This hormone is essential for the development of male reproductive tissues, the promotion of secondary sexual characteristics during puberty, and the maintenance of muscle mass, bone density, and libido throughout adulthood. However, testosterone is not a static number; it is a dynamic hormone influenced by sleep, stress, diet, and time of day. Because levels typically peak in the early morning and decline throughout the day, medical guidelines emphasize that a diagnosis of "low T," or hypogonadism, requires at least two early-morning blood tests taken when the patient is well-rested and fasted. Implementing this requirement across the massive, globally distributed population of the U.S. military presents a logistical hurdle of staggering proportions.
The backdrop to this policy is a global explosion in the testosterone replacement therapy (TRT) market. In the late 1980s, global sales of testosterone products were a mere $18 million annually. By 2025, that figure is projected to reach nearly $2 billion. This exponential growth has not been driven solely by clinical necessity but by a perfect storm of direct-to-consumer marketing, the rise of "men’s health" boutique clinics, and a digital wellness culture that often equates high testosterone with peak masculinity and success. Online influencers and "biohackers" have popularized the idea that any man over 30 with fatigue or a lack of focus is suffering from a hormonal deficiency, often ignoring the roles of burnout, poor sleep hygiene, or mental health struggles. In my own practice, I have seen an increasing number of patients who have bypassed traditional medical channels to obtain testosterone through loosely regulated online marketplaces. These men frequently present with testosterone levels four or five times the physiological norm, unaware of the long-term damage they may be doing to their cardiovascular systems and fertility.
The medical community’s caution regarding widespread TRT is rooted in a history of conflicting clinical data. For years, the primary concern was cardiovascular safety. In 2010, the Testosterone in Older Men with Mobility Limitations (TOM) study was famously halted early by its safety monitoring board. The researchers found that men in the testosterone group experienced a significantly higher rate of major adverse cardiac events—including heart attacks and strokes—compared to those in the placebo group. This study cast a long shadow over the industry for over a decade. It wasn’t until the 2023 publication of the TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) that some of these fears were mitigated. The TRAVERSE trial, which followed over 5,000 men, found that TRT did not increase the risk of major cardiac events compared to a placebo. However, the study was far from a blanket endorsement of the therapy. It revealed a statistically significant increase in the incidence of acute kidney injury, atrial fibrillation, and pulmonary embolism among those receiving testosterone. These are not minor side effects; they are life-altering conditions that require lifelong management.
In the context of the military, the data is even more specific. My own research group utilized the TRICARE database—the insurance system for military beneficiaries—to track outcomes for men using testosterone supplementation. Our findings were sobering. We identified a clear correlation between TRT use and an increased risk of developing kidney stones and obstructive sleep apnea. While our study also noted some improvements in overall cardiovascular outcomes in certain subsets, the increased risk of sleep apnea is particularly relevant for active-duty service members. Sleep apnea not only impacts daytime alertness and cognitive function—critical for those in high-stakes combat or technical roles—but it also puts additional strain on the heart and lungs over time.
One of the most significant and often overlooked risks of the DOD’s proposed screening program involves fertility. Secretary Hegseth noted that the program would target service members aged 30 and older—a demographic that is often in the prime of their reproductive lives. It is a biological fact that exogenous testosterone (testosterone taken as a supplement) acts as a form of male contraception. By introducing outside testosterone into the body, the HPG axis is "shut down" because the brain senses there is already enough hormone present. This leads to a dramatic reduction in the production of follicle-stimulating hormone (FSH) and LH, which are necessary for sperm production. The result is often testicular atrophy (shrinking of the testicles) and a plummeting sperm count, which can lead to permanent infertility in some men. Both the American Urological Association (AUA) and the Endocrine Society have issued clear guidelines cautioning against the use of testosterone in men who still wish to father children. If the DOD proceeds with mass screening, they must be prepared for the reality that a significant portion of the force may inadvertently trade their future fertility for a temporary boost in performance.
The logistical "cascade of care" triggered by a mandatory screening program is another area of concern. When a screening test is mandated for a population of hundreds of thousands, a certain percentage will inevitably return a "false positive" or a borderline result. Under the current Endocrine Society guidelines, routine population-level screening of asymptomatic men is explicitly discouraged. The reason is simple: treating a number on a lab report rather than a patient with clinical symptoms leads to over-medicalization. If a 32-year-old Special Forces operator feels excellent, performs at the top of his class, but has a testosterone level slightly below the reference range due to overtraining or lack of sleep, should he be placed on a lifelong medication? Once a service member starts TRT, they require constant monitoring of their hematocrit levels (to check for blood thickening), PSA levels (to monitor for prostate cancer risks), and liver function. Scaling this level of specialized, individualized care to the entire Department of Defense health system would be an administrative and financial undertaking of historic proportions.
Furthermore, there is the question of the "experiment" itself. By mandating this screening, the DOD is essentially conducting a massive, uncontrolled longitudinal study on the hormonal manipulation of the American fighting force. While Hegseth has stated that the choice to take supplements would remain with the individual service member, the culture of the military often makes "optional" programs feel mandatory for those seeking promotion or elite status. If a low testosterone score is seen as a mark of reduced "readiness," service members will feel immense pressure to medicate, regardless of the risks. This creates an ethical quagmire: are we treating a medical condition, or are we attempting to "engineer" a more aggressive or muscular soldier?
The medical management of testosterone is a nuanced field that requires a high degree of personalization. It is not a one-size-fits-all solution for the challenges of aging or the rigors of military service. While there is no doubt that testosterone replacement can improve muscle mass, libido, and mood in men with legitimate clinical hypogonadism, the risks of heart rhythm issues, blood clots, and infertility cannot be ignored. For the wellness of our military, it is critical that any testing program be accompanied by rigorous, independent oversight and a robust system for monitoring long-term side effects. We must ensure that the "optimization" of our troops does not come at the cost of their long-term health and the stability of their families. The decision to move forward with this program represents a novel experiment without precedent, and the stakes—both for the individuals involved and the readiness of the U.S. military—could not be higher. As this policy takes shape, the focus must remain on the evidence-based practice of medicine, ensuring that we are not led astray by the allure of a quick hormonal fix for the complex challenges of modern military life.
